GreenRoc Accelerates their World Class Project to Production as Early as 2028. Watch the full video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Is they can’t be burning ?? £3 mill a month yet as nothing is happening!!!
au contraire!! The cost of employing a CRO and the associated costs of running clinical trials is extremely significant. The later the Phase the higher the costs....
We were funded for 2 years. Now 15months remaining.
At least we will have enough in the bank for the FY statement (Dec 20) to be a 'going concern'. Maybe towards the end of this year, funds will need to be raise, hopefully from a much higher level , to be considered a going concern for Dec 21 FY report.
FYI: The 'going concern' concept, or assumption, is an accountancy term that describes a company which can continue operating without the significant threat of liquidation, and therefore remain in business for the foreseeable future.
Onwards & upwards from some point around here!!!
BB
Good thing will come to those who are patient.
Nasal anti-CD3 is an exciting, novel approach that has the ability to provide a safe treatment for a form of MS that has no effective treatment. We are pleased that the FDA has allowed us to treat a patient with SPMS who needs a better treatment option than is currently available."
Dr. Tanuja Chitnis, Professor of Neurology at Harvard Medical School and senior neurologist at the BWH, adds, "New treatments for progressive MS are urgently needed. Nasal Foralumab could revolutionize treatment for this disabling form of disease."
The company had previously reported positive data from the Clinical Study of Nasal Administration with Foralumab in COVID-19 patients in Brazil. Nasally administered Foralumab at 100 mg/day for consecutive 10 days treatment was found to be well-tolerated, and there were no apparent severe adverse events. The clinical data suggested that the treatment provided significant reduction of lung inflammation.
Dave they ain’t running any trials at the moment!!
Perhaps they are on a beach somewhere sipping ****tails?
Any raise in the future will be for late phase 2 or 3 trials and will be above £1.50. look up the NASDAQ options. If that's not confidence I don't know what is. At that point the proverbial chickens are ready to hatch.
Still sat in the background (along with other lth's)...waiting for news. While completely bought into the science, don't understand why TILS haven't pushed TZLS-501. I initially assumed it would be used for the Brazil trial rather than Foralumab...given Tocilizumab (Actemra) from Roche is anti-IL6 and considered effective, but is IV and humanised...would have thought nasal delivery of TILS' fully human mAb would be obvious to expedite. However, while news releases have talked about expediting its progression last March, 12 months on, it's still only at IND stage / Phase 1 - due to start this quarter.
The board clearly aren't daft...so thinking the November Foralumab trial gave them the info, firstly to push to ph2 for Crohns/MS but also to look at using them in combination with 501?
The anti-vitals task force announced yesterday would suggest a huge opportunity here...must be stuff going on in the background and doubt TILS will be direct into government, but can see a tie up with a partner such as Roche who have the weight/ties to drive commercialisation (UK govt throwing money around and Roche can't target drugs for home use with IV delivery only (at the moment)...
Things too quiet currently....they aren't sat on their hands...think it could get more interesting in the not too distant...IMHO...
Hi Greend100,
It has indeed all gone eerily quiet, but I 've no doubt there is a lot going on under the bonnet here. All the regulatory authorities across the world must be stretched after being inundated with approval requests, so I guess TILS will have to face this constraint like everyone else. Perhaps a big pharma collaboration is on the cards as you mention - must be a real possibility given the apparent quality of the science.
I continue to hold as before - the upside could still be very exciting - que sera sera. Bottom drawer.
Markat, Paul is a credible poster who has had replies from the company previously.
If the UK government show an interest in what TILS is offering the SP will go through the roof.
We are lucky that we have the inside knowledge of a fully human monoclonal antibody which is more cost effective to produce than any other Mab out there and easier to administer than any other Mab out there.
Cheers for the info Paul.
Lets hope so. I wonder if a trial in India would be beneficial with the massive amount of cases. It would certainly be easy to find enough candidates however probably difficult to manage with their health service being so overwhelmed.
It just needs one politician or someone presently operating in those circles eg. Chris Witty, Patrick Vallance to reference Foralumab and this could go off the scale.
Hi Rockz. I hope you are correct. I have a large holding here and am well under water but believe in what they are doing and am happy to sit it out and wait. I view tils as a long term hold - unless they are bought out of course
Atb
Don’t worry Markat, I’ve got the snorkel on aswell at the moment, also in deep but not concerned.
I’ve seen this share price motor by 20 per cent plus in a day on many occasions now.
Currently way undervalued in my book. I’m looking for £2.60 before I even consider taking 10 per cent of my holding off the table.